CENTRAL DATA COLLECTION CENTER (CDCC) CONTINUED FOLLOW-UP OF PLCO

中央数据收集中心（CDCC）持续跟进PLCO

• 批准号: 8441458
• 负责人: BARBARA O'BRIEN
• 金额: $ 268.52万
• 依托单位: WESTAT, INC.
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-03-01 至 2016-02-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8441458
• 关键词: Biological; Clinical Data; Collection; Colon; Colorectal; Colorectal Cancer; Data; Data Collection; Data Coordinating Center; Diagnostic; Elderly; Epidemiologic Studies; Epidemiology; Life Style; Long-Term Effects; Lung; Malignant Neoplasms; Malignant neoplasm of lung; Malignant neoplasm of ovary; Medical; Molecular; National Cancer Institute; Ovarian; Ovary; Participant; Pharmaceutical Preparations; Prostate; Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial; Questionnaires; Resources; Risk; Sampling; Screening for Prostate Cancer; Screening procedure; Site; Tumor Tissue; Update; cost; design; follow-up; mortality; tumor; tumor registry

The PLCO Central Data Coordinating Center (CDCC) is an extension of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. To reduce costs, the extension has one data collection site under the direction of the National Cancer Institute (NCI) rather than the original ten PLCO Screening Centers. PLCO participants were invited to be transferred to the CDCC for continued, active follow up. Other participants agreed to be passively followed at the PLCO sites through tumor registry searches. PLCO was designed to determine if screening for prostate, lung, colorectal and ovarian cancer can reduce mortality from these cancers. In addition, PLCO has a collection of pre- and post-diagnostic biological samples stored in the PLCO Biorepostory, and epidemiological data from questionnaires. These data are a valuable resource for cutting-edge molecular epidemiologic research. The study was extended in this streamlined fashion to increase the value of the resource. The study will continue to update key exposure data by collecting additional risk and lifestyle information, including medication use and medical conditions that are common in older adults. Also, the CDCC will collect additional clinical data and tumor tissue of selected cancers, such as that of the colon and ovaries. This extension of the PLCO Cancer Screening Trial enhances the value of the PLCO resources through the substantial increase in the number of incident cancers accrued within the Trial, strengthens the Trial's ability to clarify further the long-term effects of screening on cancer mortality, and provides a final opportunity to collect additional exposure data and expand the existing tumor pathological resource within the PLCO.

PLCO中央数据协调中心（CDCC）是前列腺，肺，结直肠和卵巢（PLCO）癌症筛查试验的扩展。为了降低成本，该扩展名在国家癌症研究所（NCI）的指导下，而不是原来的十个PLCO筛查中心，有一个数据收集地点。邀请PLCO参与者转移到CDCC进行持续，积极的随访。其他参与者同意通过肿瘤注册表搜索在PLCO站点进行被动遵循。 PLCO旨在确定筛查前列腺，肺，结直肠癌和卵巢癌是否可以降低这些癌症的死亡率。此外，PLCO收集了PLCO生物验证中存储的诊断前和后诊断生物学样本，以及来自问卷的流行病学数据。这些数据是尖端分子流行病学研究的宝贵资源。该研究以这种简化的方式扩展了，以增加资源的价值。这项研究将继续通过收集额外的风险和生活方式信息，包括使用药物和医疗状况来更新关键的暴露数据。此外，CDCC将收集选定癌症（例如结肠和卵巢的癌症）的其他临床数据和肿瘤组织。 PLCO癌症筛查试验的这种扩展通过在试验中积累的事件癌的数量的大幅度增加，增强了试验进一步阐明筛查对癌症死亡率的长期影响的能力，并提供了收集额外的暴露数据并扩大PLCO中现有的Tumor病理资源的最终机会。